Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation.
Approximately 20% of patients receiving liver transplants for end-stage hepatitis C rapidly develop severe allograph fibrosis within the first 24 months after transplant. Hepatitis C virus (HCV) variants were studied in 56 genotype-1-infected subjects with end-stage hepatitis C disease at the time before and 12 months after liver transplant, and post-transplant outcome was followed with serial liver biopsies. In 15 cases, pre-transplant HCV genetic diversity was studied in detail in liver (n=15), serum (n=15), peripheral blood mononuclear cells (n=13), and perihepatic lymph nodes (n=10). Our results revealed that pre-transplant HCV genetic diversity predicted the histological outcome of recurrent hepatitis C disease after transplant. Mild disease recurrence after transplant was significantly associated with higher genetic diversity and greater diversity changes between the pre- and post-transplant time points (p=0.004). Meanwhile, pre-transplant genetic differences between serum and liver were related to a higher likelihood of development of mild recurrent disease after transplant (p=0.039).
Li
Hui
H
Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington, USA.
Sullivan
Daniel G
DG
Feuerborn
Nathan
N
McArdle
Susan
S
Bekele
Kirubeal
K
Pal
Sampa
S
Yeh
Matthew
M
Carithers
Robert L
RL
Perkins
James D
JD
Gretch
David R
DR
D000293:Adolescent; D000328:Adult; D002648:Child; D004279:DNA, Viral / Q000235:genetics*; D005260:Female; D014644:Genetic Variation; D016174:Hepacivirus / Q000145:classification* / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000601:surgery / Q000821:virology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D008099:Liver / Q000821:virology; D016031:Liver Transplantation; D008198:Lymph Nodes / Q000821:virology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012367:RNA, Viral / Q000235:genetics*; D012008:Recurrence; D044967:Serum / Q000821:virology; D016896:Treatment Outcome; D055815:Young Adult
D004279:DNA, Viral; D012367:RNA, Viral
J Virol. 2008 Aug;82(15):7524-32
18495766
Gastroenterology. 1999 Oct;117(4):926-32
10500076
J Virol. 2005 Jul;79(14):9145-56
15994809
Mol Biol Evol. 1987 Jul;4(4):406-25
3447015
J Hepatol. 2000 Apr;32(4):673-84
10782918
J Hepatol. 1998 May;28(5):756-63
9625309
Am J Surg Pathol. 1995 Dec;19(12):1409-17
7503362
Hepatology. 1999 Jan;29(1):217-22
9862869
Gastroenterology. 2006 Apr;130(4):1107-16
16618405
Gastroenterology. 2002 Nov;123(5):1485-93
12404223
Science. 2000 Apr 14;288(5464):339-44
10764648
Gastroenterology. 1995 Apr;108(4):1088-96
7698576
J Hepatol. 1998 Dec;29(6):887-92
9875634
Liver Transpl. 2002 Nov;8(11):1014-9
12424714
Hepatology. 1998 Sep;28(3):823-30
9731579
Liver Transpl. 2004 Feb;10(2):208-16
14762858
Hepatology. 2004 Mar;39(3):817-25
14999702
J Virol. 2002 Jan;76(2):600-8
11752151
Virology. 1998 Aug 15;248(1):164-71
9705266
J Infect Dis. 2002 Feb 15;185(4):417-21
11865392
Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S125-31
16234060
J Gen Virol. 1995 May;76 ( Pt 5):1197-204
7730804
J Gen Virol. 1995 Jul;76 ( Pt 7):1763-71
9049381
N Engl J Med. 1996 Mar 28;334(13):815-20
8596547
J Virol. 1996 Nov;70(11):7622-31
8892882
J Virol. 1999 Nov;73(11):9213-21
10516029
J Hepatol. 1999 Oct;31(4):618-27
10551384
Virology. 2008 Jun 5;375(2):580-91
18343477
J Virol. 1998 Feb;72(2):1640-6
9445070
Mol Biol Evol. 1986 Sep;3(5):418-26
3444411
Surg Today. 2003;33(6):421-5
12768367
Virology. 1991 Feb;180(2):842-8
1846505
J Virol. 1998 Dec;72(12):10036-43
9811742
Science. 1996 Jul 26;273(5274):415-6
8677432
J Med Virol. 2001 Oct;65(2):266-75
11536232
J Virol. 2000 Jan;74(2):1014-7
10623766
Hepatology. 1995 Jul;22(1):1-9
7601397
Nucleic Acids Res. 1994 Nov 11;22(22):4673-80
7984417
Hepatology. 1995 Jan;21(1):30-4
7806166
J Gastrointestin Liver Dis. 2007 Mar;16(1):65-73
17410291
J Infect Dis. 1997 May;175(5):1101-7
9129072
J Hepatol. 2005 Apr;42(4):491-8
15763335
J Virol. 2005 May;79(10):6349-57
15858018